Estudo futura: avaliação da eficácia e segurança do fumarato de rupatadina no tratamento da rinite alérgica persistente
| Autor: | Mion,Olavo de Godoy, Campos,Regis A., Antila,Martti, Rapoport,Priscila Bogar, Rosario,Nelson, Mello Junior,João Ferreira de, Guimarães,Roberto Eustáquio Santos, Mocellin,Marcos, Di Gesu,Giovanni, Solé,Dirceu, Wexler,Luc, Mello,João Ferreira de, Castro,Fábio Morato, Chavarria,Maria Letícia |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: | |
| Zdroj: | Brazilian Journal of Otorhinolaryngology, Volume: 75, Issue: 5, Pages: 673-679, Published: OCT 2009 Brazilian Journal of Otorhinolaryngology v.75 n.5 2009 Brazilian Journal of Otorhinolaryngology Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF) instacron:ABORL-CCF |
| Popis: | Allergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|